ABSTRACT
Background Respiratory syncytial virus (RSV) causes significant disease burden in infants and older adults. Most vaccines in development focus on the virus’s F protein. MVA-BN-RSV is a novel vectored vaccine encoding internal and external proteins from both RSV subtypes.
Methods In a phase 2a trial, participants aged 18 to 50 years selected for low RSV titers were randomized to receive MVA-BN-RSV or placebo, then challenged 4 weeks later with RSV-A Memphis 37b. Viral load was assessed from nasal washes and virus cultivation, and RSV symptoms were collected throughout quarantine. Antibody titers and cellular markers were assessed before and after vaccination and challenge.
Results Of 74 participants randomized, 36 received MVA-BN-RSV and 37 received placebo; 31 and 32, respectively, were challenged. Viral load areas under the curve from nasal washes were lower (p=0.017) for MVA-BN-RSV (median=0.00) compared to placebo (median=49.05). Total symptom scores also were lower with MVA-BN-RSV. Vaccine efficacy in preventing infection confirmed by viral culture was 88.5% (CI: 14.8%; 98.5%). Immunoglobulin A and G in serum increased about 4-fold after MVA-BN-RSV vaccination, which was greater than the placebo response to challenge, and neutralizing antibody titer increased about 2-fold. Cellular responses were robust, particularly to the internal RSV proteins. Injection site pain occurred more frequently with MVA-BN-RSV. No serious adverse events were attributed to vaccination.
Conclusion MVA-BN-RSV vaccination resulted in lower viral load and was effective against laboratory-confirmed symptomatic infection. Humoral and cellular responses support broad immunogenicity of the vaccine. No safety issues were identified with vaccination.
Clinical Trial Registry Number NCT04752644
Competing Interest Statement
Golam Kabir: former employee of hVIVO Elke Jordan, Stephanie Schultz, Günter Silbernagl, Darja Schmidt, Daria Stroukova, Barbara Martin, Victoria Jenkins, Heinz Weidenthaler, Laurence De Moerlooze: current employees of Bavarian Nordic
Clinical Trial
NCT04752644
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT04752644?term=NCT04752644&draw=2&rank=1
Funding Statement
This study was funded by the sponsor and vaccine manufacturer, Bavarian Nordic A/S.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Committee A of Health and Social Care (HSC) Business Services Organisation gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations: The trial protocol was reviewed and approved by the Ethics Committee prior to its start, and subjects provided written informed consent before participating in the trial. The trial was conducted according to the principles of the Declaration of Helsinki and was performed in compliance with Good Clinical Practices and the approved protocol.
Data Availability
Data produced in the present study may be available upon reasonable request to the authors
